Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIFA-SNAP
NCT07253688Phase 3Terminated
- Start
- Nov 2025
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of rifampicin in Prosthetic valve endocarditis (PVE) (2 arms). Primary endpoint: Treatment failure at 180 days. Started Nov 2025; status: terminated.
02
Drugs
rifampicin
03
Conditions
Prosthetic valve endocarditis (PVE)
Beyond the preview
Go deeper on NCT07253688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07253688.